Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 392

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1C
Chunk 392
---
     (140)
  
    Long-term operating lease liabilities 
    $244 

F-19

During the years ended December 31, 2024 and 2023,
the Company recognized $161,000 and $163,000, respectively, in operating lease expense, which is included in general and administrative
expenses in the Company’s consolidated statement of operations.

Dispute

The Company
has an ongoing dispute with a vendor in which the Company believes that the vendor did not properly provide services for which they have
invoiced the Company. As of December 31, 2024, the Company has outstanding invoices with the vendor which aggregate approximately $1.6 million,
of which the Company has recorded approximately $0.2 million, which is the Company’s estimate of the obligation incurred, and
the remaining $1.4 million has not been recorded by the Company as the Company believes the invoices were sent erroneously. The Company
and the vendor are still attempting to resolve the dispute and legal proceedings have not been threatened.

Litigation

The Company
is subject to claims and suits that arise from time to time in the ordinary course of our business. Although management currently believes
that resolving claims against the Company, individually or in aggregate, will not have a material adverse impact in the Company’s
consolidated financial statements, these matters are subject to inherent uncertainties and management’s view of these matters may
change in the future. 

NOTE
13 – SEGMENT INFORMATION

The Company
operates as one operating segment. The Company’s chief operating decision maker (“CODM”) is its Chief Financial Officer,
who reviews the financial statements on a consolidated basis. The CODM uses the Company’s long-range plan to allocate resources.
The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using
consolidated loss from operations. 

Significant expenses
within loss from operations, as well as within net loss, include research and development and general and administrative expenses, which
are each separately presented on the Company’s Consolidated Statements of Operations and Comprehensive Loss. Other segment items
within net loss include other income (expense), net.

The Company’s long-lived
assets consist primarily of acquired in-process research and development intangible assets which are located in the United States.

NOTE
14 – SUBSEQUENT EVENTS

Cordstrom License Agreement 

On February 6, 2025, the Company and GOSH entered into a license agreement